Related Experiment Video
Updated: May 12, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Aspirin resistance in Thai patients with chronic stable angina
Rewat Phankingthongkum1, Pradit Panchavinnin, Yingyong Chinthammitr
1Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. rewat.pha@mahidol.ac.th
Insights
Aspirin resistance affects 21.6% of Thai patients with chronic stable angina. This study found no significant clinical risk factors associated with aspirin resistance in this patient group.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Aspirin is a cornerstone therapy for chronic stable angina.
- Aspirin resistance is a growing concern, potentially impacting treatment efficacy.
- Understanding aspirin resistance prevalence and risk factors is crucial for optimizing patient care.
Purpose of the Study:
- To determine the prevalence of aspirin resistance in Thai patients with chronic stable angina.
- To identify clinical profiles and potential risk factors associated with aspirin resistance.
Main Methods:
- Prospective recruitment of 157 patients diagnosed with chronic stable angina.
- Blood samples analyzed for hemoglobin, platelet count, and platelet aggregation using light transmittance aggregometry.
- Aspirin resistance defined by specific thresholds for adenosine diphosphate (ADP) and arachidonic acid-induced platelet aggregation.
Main Results:
- The prevalence of aspirin resistance was 21.6% (34 out of 157 patients).
- Patients with aspirin resistance had a mean age of 66 years, with 58.8% being male.
- No statistically significant association was found between aspirin resistance and factors like age, gender, BMI, diabetes, hypercholesterolemia, smoking, or PPI use.
Conclusions:
- The prevalence of aspirin resistance in Thai patients with chronic stable angina is 21.6%.
- No significant associations were identified between common clinical factors and aspirin resistance in this cohort.
- Further research may be needed to explore other potential contributors to aspirin resistance.
Objective:
To determine the prevalence, clinical profile and risk factors of aspirin resistance in Thai patients with chronic stable angina.
Material And Method:
The patients were prospectively recruited from the consecutive patients diagnosed chronic stable angina at Siriraj Hospital during March 2011 to February 2012. Ten milliliter of blood samples were cautiously drawn from the antecubital vein of the patients to determine the hemoglobin, platelet count and platelet aggregation test performed by light transmittance aggregometry using platelet-rich plasma. Platelets were stimulated with 0.5 mg/ml of arachidonic acid and 10 mM adenosine diphosphate. Platelet aggregation was expressed as the maximal percent change in light transmittance from baseline. Aspirin resistance was defined as the mean platelet aggregation of > or = 70% with 10 mM ADP and the mean platelet aggregation of > or = 20% with 0.5 mg/ml of arachidonic acid.
Results:
One-hundred and fifty seven patients diagnosed chronic stable angina were enrolled in the present study. There were 34 patients (21.6%) demonstrating aspirin resistance. The clinical characteristic of these patients included male 58.8% with mean age of 66 years, body mass index 27.5 kg/m2, diabetes mellitus 52.9%, smoking 8.8%, hypercholesterolemia 70.6% and proton pump inhibitor use 23.5%. Multivariate analysis demonstrated none of the risk factors including age, female, body mass index, diabetes mellitus, hypercholesterolemia, smoking and proton pump inhibitor (PPI) use had a statistically significant association with aspirin resistance.
Conclusion:
Our study demonstrated that the prevalence of aspirin resistance in Thai patients with chronic stable angina was 21.6%. No significant association was demonstrated between age, female, body mass index, diabetes mellitus, hypercholesterolemia, smoking, proton pump inhibitor (PPI) use and aspirin resistance.
Related Concept Videos
Angina II: Classification
Angina IV: Management
Angina V: Nursing Management
Angina III: Clinical Manifestations and Assessment
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
